$1.06 Billion is the total value of Paradigm Biocapital Advisors LP's 25 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PRTA | Exit | PROTHENA CORP PLC | $0 | – | -75,000 | -100.0% | -0.53% | – |
ARVN | Exit | ARVINAS INC | $0 | – | -599,599 | -100.0% | -2.41% | – |
KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -106,210 | -100.0% | -2.45% | – |
AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -604,544 | -100.0% | -3.89% | – |
HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -477,585 | -100.0% | -6.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
INCYTE CORP | 7 | Q3 2023 | 8.6% |
ARGENX SE | 7 | Q3 2023 | 8.7% |
UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-02 |
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.